|
| |
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
i
| |
| |
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii
|
Summit Therapeutics PLC
Sedol BN40HZ0
| |
2 Reason for the notification
(please tick the appropriate box or boxes):
| | An acquisition or disposal of voting rights | | | An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | | | An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | | | An event changing the breakdown of voting rights | | | Other (please specify): | Voluntary baseline disclosure upon implementation of amendments to the Transparency Directive | X |
3. Full name of person(s) subject to the
notification obligation:
iii
|
1
Lansdowne Partners International Limited
2
Lansdowne Partners Limited
3
Lansdowne Partners (UK) LLP
|
4. Full name of shareholder(s)
(if different from 3.):iv
|
HSBC Client Holdings Nominee (UK) Ltd,
HSBC Bank Plc Lansdowne Markets
(Registered Shareholders)
|
5. Date of the transaction and date on
which the threshold is crossed or
reached:
v
| 26/11/2015 | |
6. Date on which issuer notified:
| 30/11/2015 |
7. Threshold(s) that is/are crossed or
reached:
vi, vii
| Voluntary baseline disclosure upon implementation of amendments to the Transparency Directive |
|
8. Notified details:
| |
A: Voting rights attached to shares
viii, ix
|
Class/type of
shares
if possible using
the ISIN CODE
|
Situation previous
to the triggering
transaction
|
Resulting situation after the triggering transaction
|
Number
of
Shares
|
Number
of
Voting
Rights
|
Number
of shares
|
Number of voting
rights
|
% of voting rights
x
| |
Direct
|
Direct
xi
|
Indirect
xii
|
Direct
|
Indirect
| | Ordinary Shares | 11,077,170 | 11,077,170 | | | 11,077,170 | | 18.07% | | GB00BN40HZ01 | | | |
B: Qualifying Financial Instruments
| |
Resulting situation after the triggering transaction
|
Type of financial
instrument
|
Expiration
date
xiii
|
Exercise/
Conversion Period
xiv
|
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
|
% of voting
rights
| | American Depositary Shares (ADS) | N/A | N/A | 4,650,000 | 7.59% | | | |
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
xv, xvi
| |
Resulting situation after the triggering transaction
|
Type of financial
instrument
|
Exercise price
|
Expiration date
xvii
|
Exercise/
Conversion period
xviii
|
Number of voting rights instrument refers to
|
% of voting rights
xix, xx
| | | | | |
|
Nominal
|
Delta
| | | | | | |
Total (A+B+C)
| |
Number of voting rights
|
Percentage of voting rights
| | 15,727,170 | 25.66% |
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi
| | Lansdowne Partners International Limited is the parent undertaking of Lansdowne Partners Limited which is the First Corporate Member of Lansdowne Partners (UK) LLP | |
| |
Proxy Voting:
| |
10. Name of the proxy holder:
| |
11. Number of voting rights proxy holder will cease
to hold:
| |
12. Date on which proxy holder will cease to hold
voting rights:
| | | |
13. Additional information:
|
Based on total voting rights of 61,290,740
| |
14. Contact name:
| Ruari Paton | |
15. Contact telephone number:
| +44 020 7290 5500 |
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via GlobeNewswire
HUG#1970344
|
